Pugazhendi Vijayaraman, MD, is the director of cardiology at Geisinger Wilkes-Barre.

LEADR LBBAP: Sternum Lead Implantation Safe for CRT-D or ICD Patients

Final results from the LEADR LBBAP study have indicated the safety and efficacy of implanting leads from below the sternum in patients receiving a 

 therapy defibrillator (CRT-D) or implantable cardioverter-defibrillator (ICD).

These data were presented at the Heart Rhythm Society 2026 Showcase in Chicago, Illinois, as a late-breaking trial by Pugazhendhi Vijayaraman, MD, director of cardiology at Geisinger Wilkes-Barre. Following the conference, the editorial team at 

 spoke with Vijayaraman to learn more about the study and its implications for patients.

“Where I see value with the lead is in one of the challenges that we’ve had – while we’ve found that left frontal branch area pacing works very well in many patients who need CRT and with outcomes comparable to traditional BI ventricular pacing, this involved placing 2 leads,” Vijayaraman told 

. “That presence of 2 leads in the right ventricle is a new problem. This allows us to convert those 2 leads into 1 lead.”

The LEADR LBBAP study was a companion to the LEADR study, which aimed to assess the safety and efficacy of the Next Generation ICD lead. LEADR LBBAP involved implanting the lead in the left bundle branch area pacing location in patients with ICD and LOT-CRT. Collectively, both studies were conducted across 55 locations worldwide.

Patients were eligible for inclusion in LEADR LBBAP if they met the current local clinical practice guidelines for ICD implantation or CRT-D system and will undergo either de novo Medtronic ICD system implant or de novo Medtronic CRT-D system implant, among other criteria. Patients were excluded if they had a contraindication for screw-in active fixation transvenous lead placement, an existing pacemaker, pre-existing or suspected pneumothorax, severe aortic stenosis, or unstable angina, among other criteria.

The primary endpoints for LEADR LBBAP were the percentage of subjects successfully defibrillated at implant with the Next Generation ICD lead and lead-related major complication rates at 3 months.

A total of 316 patients had a LBBAP implant attempt – of these patients, 29% were female, and the average age was 64.9 +/- 12.2 years. Freedom from major study lead-related major complications at 6 and 12 months were 97.7% and 96.8%, respectively (n = 8 complications). Additionally, throughout follow-up (9.9 +/- 4 months), the most common major complication was lead dislodgement (n = 4). For the 143 patients receiving LOT-CRT, Vijayaraman and colleagues noted a significant reduction in QRSd between baseline and LOT-CRT (170 +/- 29.8ms to 145.3 +/- 22.1ms; 

Left ventricular ejection fraction improved from baseline to 6 months by a factor of 8.5% (

 <.001), while quality of life improved from baseline to 6 months (KCCQ improvement, 14.2 +/- 20.1 points; 

 <.001; CCS: 85% improved or stabilized).

“The benefits of this approach have to outweigh any risks in the long term, which is why we need a comparison study,” Vijayaraman said. “Historic biventricular pacing studies have provided a 70% clinical and echocardiographic response rate. Our goal is to improve that response rate closer to 90% or higher, and that’s feasible when we combine these approaches – we can get the best of both worlds.”

Editors’ Note: Vijayaraman reports disclosures with Abbott Laboratories, Boston Scientific, Biotronik, and Medtronic.

Vijayaraman P, Mason PK, Liu X, et al. EN-527958-005 longer-term safety and lot-CRT functional outcomes using a novel, small-diameter defibrillation lead: Final results of the LEADR LBBAP clinical trial. Heart Rhythm. 2026;23(4). 

Medtronic Cardiac Rhythm and Heart Failure. Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP). ClinicalTrials.gov Identifier: NCT04863664. Updated December 9, 2025. Accessed May 13, 2026. 

https://clinicaltrials.gov/study/NCT04863664

Videos

Pugazhendhi Vijayaraman, MD, discusses his recent presentation of the final results of LEADR LBBAP, simplifying the lead placement problems faced by earlier models.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

In an analysis of Global Burden of Disease (GBD) 2023 data, worldwide 

 burden is projected to rise significantly through 2050, with uniquely steep increases projected in lower- and middle-income areas of the world.

These findings and others were authored by Youyou Zhou, MD, PhD, from Shenzhen People’s Hospital in China. Zhou and colleagues assessed trends from 1990 - 2023 for cutaneous squamous cell carcinoma (cSCC), malignant melanoma, and basal cell carcinoma (BCC), with their focus being an examination of prevalence and disability-adjusted life-years (DALYs).

The team also assessed differences by characteristics such as age, sex, and Sociodemographic Index (SDI). The latter characteristic was noted by Zhou et al as a composite indicator incorporating fertility rates, attainment of education, and income per capita.

“Malignant skin cancers impose an escalating and heterogeneous health burden worldwide,” the investigative team said.

 “Using the Global Burden of Disease (GBD) 2023 database, we summarize these cancers’ epidemiology, subgroup patterns, and projections to 2050.”

Which Skin Cancer Patterns Were Observed?

In their estimation of future burden through 2050, Zhou and coauthors implemented a Bayesian age-period-cohort modeling approach, which accounts for temporal, age-associated, and generational impacts while generating uncertainty estimates around projections. In their assessment of BCC, the team did not include data from 2005-2009 given surveillance-related distortions and instead modeled future trends implementing data collected in the timeframe between 2010 - 2023.

The data noted by the team demonstrated marked geographic disparities in the level of observed skin cancer burden. In 2023, Zhou et al noted, the highest melanoma rates of prevalence were seen in Oceania, exceeding 300 cases per 100,000 patients. They also found cSCC rates were greatest in wealthier Western nations, particularly the US, wherein rates surpassed 200 cases per 100,000 members of the population. BCC prevalence was also highest in North America, Oceania, and in Northern European countries.

DALYs were also found by Zhou and colleagues to be disproportionately concentrated in high-SDI areas of the globe, although trends related to incidence still varied considerably across geographic and economic settings over the course of time. Low- and middle-SDI regions reported persistent levels of growth in incidence between 1990 - 2023 across all 3 types of skin cancer. Especially sharp increases in melanoma incidence were noted in East Asia and Andean Latin America, where prevalence increased by more than 250% during the study period.

Comparable upward patterns were also identified by Zhou and coauthors in high-income Asia-Pacific countries. By contrast, North American trends diverged by the subtype of cancer. Incidence of melanoma dipped modestly in high-income North America, falling by approximately 10%. cSCC and BCC incidence, however, rose substantially by more than 150% and 30%, respectively. While decreases in melanoma DALYs occurred globally, the largest dips were seen in high-SDI areas, including North America and Central Asia.

Meanwhile, cSCC-related DALYs rose considerably in lower-SDI settings. BCC-associated DALYs were relatively stable overall, though notable increases occurred in East Asia and high-income Asia-Pacific regions. Sex-based analyses showed consistently greater prevalence rates among male individuals for all 3 cancers. In 2023, melanoma prevalence reached 28.2 cases per 100,000 males compared with 25.6 cases per 100,000 females. Despite this disparity, melanoma prevalence declined between 2010 - 2023 in both sexes.

Data that were stratified by age suggested melanoma prevalence rose most dramatically among those who were aged 70 years and older, whereas younger adults in the 30-49 year age bracklet experienced declining rates. The team further noted population growth had been a major driver behind rising BCC and cSCC case counts. Zhou et al further identified broader epidemiologic shifts as contributors to melanoma increases, especially among those in lower-middle and middle-SDI regions.

Projections described by the investigative team pointed to continued escalation in skin cancer burden across the globe through mid-century. By the year 2050, melanoma DALYs were expected to surpass 3.3 million globally. Additionally, cSCC DALYs could approach 4 million and BCC was projected to account for the greatest increase in total burden, nearing 5 million DALYs overall. The team highlighted lower- and middle-SDI areas of the world as likely to deal with the steepest increases across all 3 forms of malignancy.

“Findings of this cross-sectional study indicate distinct regional patterns,” the investigators concluded.

 “Low- and middle-SDI settings demonstrated increasing trends across all 3 cancers, while high-SDI settings showed heterogeneous patterns with melanoma burden stabilizing in some regions and continued challenges in basal cell carcinoma management.”

Zhou Y, Zhong W, Zhang J, et al. Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050. JAMA Dermatol. Published online May 13, 2026. 

Zhang W, Zeng W, Lu H, et al. Global, regional and national incidence, mortality and disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019. Cancer Med. 2021 Jul;10(14):4905-4922. doi: 10.1002/cam4.4046. Epub 2021 Jun 9. PMID: 34105887; PMCID: PMC8290243.

Articles

Investigators used the Global Burden of Disease (GBD) 2023 database to summarize skin cancers’ epidemiology, patterns, and projections to 2050.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Global Skin Cancer Patterns From 1990 - 2023, Projections to 2050 Identified

Lucas Boersma, MD, PhD, is a cardiologist at St. Antonius Hospital Department of Cardiology and professor of cardiology at the Academic Medical Center, University of Amsterdam.

Aurora EV-ICD Protects Against Dangerous Arrhythmias in Post Approval Registry

Medtronic’s Aurora EV-ICD system has demonstrated high anti-tachycardia pacing (ATP) success, effective defibrillation, and more in patients with dangerous 

, according to 1-year data from the Enlighten study, a Post Approval Registry of the device.

These data were presented at Heart Rhythm 2026 in Chicago by Professor Lucas Boersma, MD, PhD, a cardiologist at St. Antonius Hospital Department of Cardiology and professor of cardiology at the Academic Medical Center, University of Amsterdam. The presentation built on the 6-month results presented at the Asia Pacific Heart Rhythm Society Scientific Session 2025. After the meeting, the editorial team at 

 spoke with Boersma in an exclusive video interview.

00:06:26 Patient characteristics predisposing complications

“There are issues when you have to implant transvenous leads – they can become defective, there can be infections, you may have to remove the leads,” Boersma told 

. “On the other hand, we already have the S-ICD, which is a subcutaneous ICD with the leads under the skin – but the downside of that is that there are no pacing capabilities. The EV-ICD is something in between, because it has all the diagnostic capabilities and the size and shape of a transvenous device, but it doesn’t have the lead in the vascular system.”

The Enlighten study is an ongoing global, prospective, observational, multi-site registry study conducted within Medtronic’s post-market surveillance platform. The trial aimed to confirm the safety and effectiveness of the EV-ICD in routine clinical practice following the device’s commercial release.

Patients were eligible for inclusion if they were intended to receive or be treated with an EV-ICD device System and had been enrolled prior to the implant procedure. Patients who were or would be inaccessible to follow-up, as well as those currently enrolled in any concurrent drug and/or device study that could confound the Enlighten results, were excluded from the study.

The study’s primary endpoint was complication-free survival rate, defined as 5-year Aurora EV-ICD major system-related complication-free survival >79%. Secondary endpoints included system and/or procedure-related complication-free survival, abnormal battery depletion complications, patient deaths, extracardiac pacing sensations, asystole pacing, lead location, and lead motion at implant, among others.

A total of 787 patients were ultimately enrolled in the Enlighten study. In these patients, ATP successfully avoided 65 shocks in 22 patients, with a high termination rate (GEE-estimated success: 74.2%) consistent with both transvenous ICDs and the EV-ICD Pivotal Trial results. Additionally, the system displayed a low risk of complications, with 95.8% of patients free from chronic major system-related complications through 1 year and 100% of all spontaneous potentially lethal VT/VF episodes treated successfully.

These benefits were also consistent across age groups – roughly 17% of enrolled patients were ≥65 years old, and 83% were <65. Boersma and colleagues noted no difference in safety or effectiveness between age groups.

Boersma did address a potential learning curve for the new implant, emphasizing the relative novelty of implanting leads below the sternum. However, he also noted that all participating clinicians in Enlighten received sufficient training, showing that the process is absolutely replicable in a clinical setting.

“The implant under the sternum is still something new, so people will still need to get accustomed to that, and it is not devoid of risk,” Boersma said. “Proper training is needed, and it’s probably not as safe as putting the lead over the sternum under the skin. There is a tradeoff – but not all patients need placement under the sternum.”

Editors’ Note: Boersma reports consultant and proctor fees paid to Medtronic and Boston Scientific.

Medtronic. Medtronic Aurora EV-ICD system delivers exceptional one-year performance in the Enlighten real-world study. April 25, 2026. Accessed May 13, 2026. 

https://news.medtronic.com/Medtronic-Aurora-EV-ICD-TM-system-delivers-exceptional-one-year-performance-in-the-Enlighten-real-world-study

Medtronic. Enlighten Study: The EV-ICD Post Approval Registry. ClinicalTrials.gov Identifier: NCT06048731. Updated July 30, 2025. Accessed May 13, 2026. 

https://clinicaltrials.gov/study/NCT06048731

Lucas Boersma, MD, PhD, discusses the 1-year results of the Enlighten study, highlighting effective defibrillation, low rate of complications, and high ATP success.

Arrhythmia

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The US Food and Drug Administration (FDA) has approved Lupin Pharmaceuticals’ Abbreviated New Drug Applications for Famotidine Injection USP, 20 mg/2 mL (10 mg/mL), Single-Dose Vials, bioequivalent to the reference listed drug (RLD), Pepcid Injection, 10 mg/mL of Merck Sharp & Dohme Corp.

As described in a May 13, 2026, press release from the Company, the product would be manufactured at Lupin's Nagpur facility in India.

Famotidine is a histamine-2 (H2) receptor antagonist that reduces gastric acid secretion and is used to treat gastrointestinal conditions associated with excess acid production. It is available both by prescription and over the counter (OTC).

The drug was developed in Japan and has been marketed since 1981 in the United States and elsewhere under the trade name Pepcid. Of note, the patents on famotidine expired in 2001, after which generic versions came onto the market.

Prescription indications for famotidine approved by the FDA include the treatment of duodenal and gastric ulcers, gastroesophageal reflux disease (GERD) in adults and children, and pathological hypersecretory conditions in adults. OTC formulations are approved for the prevention and treatment of heartburn associated with GERD in both adult and pediatric populations.

According to the manufacturer’s package insert, famotidine is available in multiple formulations, including IV solution, oral suspension, and tablets in strengths of 10 mg, 20 mg, and 40 mg. Like its RLD, the now-approved 20 mg/2 mL (10 mg/mL) injection from Lupin is indicated for intravenous use in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in patients who are unable to take oral medication for the short term treatment of active duodenal ulcer, active benign gastric ulcer, GERD, maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer and treatment of pathological hypersecretory conditions.

The decision comes on the heels of another approval granted to Lupin on May 5, 2026, for the Company’s Abbreviated New Drug Applications for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, which is bioequivalent to the reference listed drug, Ravicti Oral Liquid, 1.1 grams per mL, of Horizon Therapeutics. It is indicated for chronic management of patients with urea cycle disorders that cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

Lupin Pharmaceuticals. Lupin Receives U.S. FDA Approval for Famotidine Injection, USP. May 13, 2026. Accessed May 13, 2026. 

https://www.prnewswire.com/news-releases/lupin-receives-us-fda-approval-for-famotidine-injection-usp-302771378.html

Patel P, Ahlawat R. Famotidine. StatPearls. September 14, 2025. Accessed May 13, 2026. 

https://www.ncbi.nlm.nih.gov/books/NBK534778/

American Chemical Society. Famotidine. August 3, 2020. Accessed May 13, 2026. 

https://www.acs.org/molecule-of-the-week/archive/f/famotidine.html

Lupin Pharmaceuticals. Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid. May 5, 2026. Accessed May 13, 2026. 

https://www.prnewswire.com/news-releases/lupin-receives-us-fda-approval-for-glycerol-phenylbutyrate-oral-liquid-302762977.html

The FDA approved Lupin’s ANDA for famotidine injection USP 20 mg/2 mL (10 mg/mL) single-dose vials, bioequivalent to Pepcid Injection (Merck). Manufacturing is planned at Lupin’s Nagpur, India facility. Famotidine, an H2-receptor antagonist first marketed as Pepcid in 1981, has long been available following patent expiry in 2001. The injectable formulation is intended for intravenous use in select hospitalized patients, including those with pathological hypersecretory states or intractable ulcers, and for short-term use when oral therapy is not feasible.

The FDA approved Abbreviated New Drug Applications from Lupin Pharmaceuticals for Famotidine Injection USP, 20 mg/2 mL (10 mg/mL), Single-Dose Vials.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Gastroesophageal Reflux Disease (GERD)

The HCPLive gastroesophageal reflux disease page is a comprehensive resource for clinical news and insights on GERD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for reflux disease, and more.

FDA News

FDA Approves Famotidine Injection USP Single-Dose Vials

Need for Head-to-Head Adjunctive MDD Data, With Leslie Citrome, MD

A network meta-analysis presented as a late-breaking session at the 2026 Neuroscience Education Institute (NEI) Spring Congress in Kissimmee, Florida, suggested lumateperone (CAPLYTA) demonstrated favorable efficacy outcomes and limited weight gain and akathisia risk compared with other FDA-approved adjunctive atypical antipsychotics for 

, investigator Leslie Citrome, MD, MPH, a clinical professor of psychiatry and behavioral sciences at New York Medical College, said direct comparative data remain needed to clarify differences between therapies in clinical practice. He said that clinicians should interpret the findings within the context of indirect evidence and the broader limitations of registrational clinical trial populations.

“The limitation that’s really key is that not all studies that were done were included—only those that led to approval by the FDA and that are mentioned in product labeling,” Citrome said.

The analysis indirectly compared lumateperone with aripiprazole, brexpiprazole, cariprazine, and quetiapine XR using placebo plus antidepressant therapy as a common comparator across 10 randomized placebo-controlled registrational trials. Citrome and colleagues reported lumateperone showed the greatest effect size across 4 efficacy outcomes, including Montgomery-Åsberg Depression Rating Scale (MADRS) change from baseline (mean difference, -4.71; 95% credible interval [CrI], -5.78 to -3.63), MADRS response (odds ratio [OR], 2.33; 95% CrI, 1.77 to 3.05), MADRS remission (OR, 2.22; 95% CrI, 1.57 to 3.07), and Clinical Global Impression-Severity (CGI-S) (-0.60; 95% CrI, -0.74 to -0.46) improvements.

According to Citrome, another important limitation involves the characteristics of patients enrolled in randomized controlled trials, which may differ from those of patients routinely seen in practice. Clinical trial participants must provide informed consent, attend scheduled visits, and often receive compensation for participation, creating what he described as a “quasi-artificial environment.”

Patients with suicidal ideation or elevated suicide risk are also commonly excluded from adjunctive MDD trials, potentially limiting generalizability to more complex real-world populations.

“The patients that are in the study may differ somewhat from the patients in practice, but in general, we would expect the same treatment effects overall,” Citrome said.

The findings were not unexpected to Citrome, who noted he has previously evaluated lumateperone using measures such as number needed to treat and number needed to harm. However, he suggested many practicing clinicians may still find the comparative differences among adjunctive atypical antipsychotics notable.

“The average clinician who’s not aware of this research may be a little bit surprised that these drugs are not all the same, and they’re not interchangeable,” Citrome said.

The network meta-analysis found lumateperone demonstrated no statistically significant weight gain relative to placebo plus antidepressant therapy and was the only treatment evaluated with akathisia risk comparable to placebo. Somnolence risk remained greater than placebo, consistent with the broader adjunctive atypical antipsychotic class.

Citrome emphasized that treatment selection in MDD remains individualized and should account for patient preferences and prior adverse event experiences, particularly related to weight gain, akathisia, sedation, and somnolence.

“If you’re looking for a particular drug for a particular person, you must take into account the person’s own values and preferences,” he said.

Editor’s note: Relevant disclosures for Citrome include H. Lundbeck A/S, Axsome Therapeutics, Alkermes, Otsuka America Pharmaceutical, E.R. Squibb & Sons, Neurocrine Biosciences, Teva Pharmaceutical, and others.

Lumateperone Ranked Favorably Among Adjunctive MDD Therapies, With Leslie Citrome, MD

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis. JNJ.com. Published May 4, 2026. Accessed May 12, 2026. 

https://www.jnj.com/media-center/press-releases/caplyta-lumateperone-showed-greatest-improvement-across-key-efficacy-outcomes-among-adjunctive-mdd-treatments-in-new-network-meta-analysis

Citrome discussed the limitations of indirect comparisons and the need for head-to-head trials evaluating adjunctive atypical antipsychotics for MDD, including lumateperone.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Katalin Susztak, MD, PhD, is a Professor of Medicine and Genetics at the University of PennsylvaniaKatalin Susztak, MD, PhD, is a Professor of Medicine and Genetics at the University of Pennsylvania

Susztak, MD, PhD, offers insight into a new score that predicts which APOL1 carriers will actually develop kidney disease.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

9-Protein Plasma Score Predicts Kidney Failure Risk in APOL1 High-Risk Individuals Before Visible CKD

This segment of a recent Skin of Color Savvy podcast highlights the experts' views on education related to colorism and skin pigment-related concerns.

How to Educate Dermatology Patients on Colorism Issues, With Seemal Desai, MD, and Pearl Grimes, MD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Experts explain managing psoriasis biologic failures: reassess response, use topicals, and switch smarter to reach near‑clear skin.

Video Series

Implementing Remission Goals in Psoriasis Practice

Oral therapies offer convenience, but biologics deliver faster, stronger results; experts weigh psoriatic arthritis, dosing schedules, safety profiles, and IL-17 vs IL-23 choices.

Patient-Level Treatment Drivers — Route of Administration, Psoriatic Arthritis, and Comorbidity Considerations 

Managing Treatment Failure in Psoriasis

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Catch up on 5 notable studies and trial updates from DDW 2026!

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

DDW 2026 Recap: 5 Trials to Know

This large real-world analysis of patients with vitiligo suggests many individuals remain untreated after diagnosis.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Key Characteristics, Treatment Patterns Identified in Patients with Vitiligo

Mehdi Shishehbor, DO, PhD, is the president of the Harrington Heart & Vascular Institute at University Hospitals.

Mehdi Shishehbor, DO, PhD, discusses the 6-month results from his recent study, confirming the efficacy of the LimFlow System in patients with CLTI.

Venous Thromboembolism

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

PROMISE III: Substantial Amputation-Free Survival With LimFlow TADV in CLTI

Practicing critical care pulmonologist, Managing Director of Health Innovation at Manatt, medical analyst for NBC News and MSNBC, affiliate faculty at the University of Washington's Institute for Health Metrics and Evaluation, commissioned officer (Major) in the United States Air Force Medical Reserve Corps, and board member of the American Lung Association

Gupta discusses clinical responsibility in response to the ALA's State of the Air 2026 report.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Strategic Alliance Partnership

Eyes on Chronic Air Pollution, With Vin Gupta, MD, MPA

Erin Ferranti, PhD, MPH, is an associate professor at the Nell Hodgson Woodruff School of Nursing at Emory University and the director of the Farmworker Family Health Program.

Erin Ferranti, PhD, MPH, discusses the new guidelines and their implications for continued enhancement of both access to and outcomes of postpartum care.

Atherosclerotic Cardiovascular Disease

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Latest News

LEADR LBBAP: Sternum Lead Implantation Safe for CRT-D or ICD Patients

Global Skin Cancer Patterns From 1990 - 2023, Projections to 2050 Identified

Aurora EV-ICD Protects Against Dangerous Arrhythmias in Post Approval Registry

FDA Approves Famotidine Injection USP Single-Dose Vials

Need for Head-to-Head Adjunctive MDD Data, With Leslie Citrome, MD